Seoul Pharma Co., Ltd (018680.KQ) Stock

018680.KQ logo

Seoul Pharma Co., Ltd

018680.KQSouth Korea
Healthcare

Company profile

Seoul Pharma reported revenue of 52.15 billion KRW for fiscal year 2025, down 2.7% from fiscal year 2024, and net income of 753.64 million KRW. That is a net profit margin of 1.4% for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 52.46 billion KRW in fiscal year 2023 to 52.15 billion KRW in fiscal year 2025, 0.3% a year on average.

What stands out

  • Net income fell 55.6% in fiscal year 2025, from 1.70 billion KRW in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Seoul Pharma Co., Ltd

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well as products for schizophrenia, vitamin supplement, obesity, tonic, and menopausal syndrome. The company also provides Ator for high blood pressure treatment; Flavel to treat stroke; Axated, a peptic ulcer medication; Crestin to treat hyperlipidemia; and Weltmin and Fendigene for the treatment of obesity. It also owns patents to orally dispersible films. The company was founded in 1976 and is headquartered in Cheongju-si, South Korea.

Leadership

  • Hei Youn Hwang — CEO & Director

How much revenue does Seoul Pharma make?

Seoul Pharma reported 52.15 billion KRW in revenue for fiscal year 2025, down 2.7% from 53.58 billion KRW in fiscal year 2024.

What companies are similar to Seoul Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Korea Arlico Pharm Co.,Ltd. (260660.KQ), Sanigen (188260.KQ), Aprogen Biologics Inc. (003060.KS), Telcon RF Pharmaceutical. Inc. (200230.KQ).

Has Seoul Pharma made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 9.69 billion KRW; FY2022, 855.09 million KRW; FY2023, 3.52 billion KRW; FY2024, 1.70 billion KRW; FY2025, 753.64 million KRW. It reported a net loss in 1 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersCheongju-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
124-31, Osongsaengmyeong 6-ro, Cheongju-si, 281 58
Phone
82 43 715 5800
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Seoul Pharma Co., Ltd (018680.KQ)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/018680.KQ

LinkedInLinkedInXXYouTubeYouTube